High-Dose therapy plus stem cell transplant shows promise for AML patients
NCT ID NCT00534469
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a treatment for adults with acute myeloid leukemia (AML) in first remission. Patients received high-dose chemotherapy and radiation to kill cancer cells, followed by an autologous stem cell transplant (using their own stem cells) to restore blood cell production. After transplant, they also received aldesleukin (a protein that boosts the immune system) to help prevent relapse. The study aimed to see how well this approach worked and what side effects occurred.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
busulfan, etoposide, total-body irradiation, aldesleukin, filgrastim, cytarabine, idarubicin
What this could lead to
If successful, this approach could improve disease-free survival for AML patients in first remission, potentially reducing relapse risk.
What could go wrong
This is a completed phase 2 trial with only 60 participants, so results may not apply broadly. High-dose chemo and radiation carry significant side effects, and the transplant may not prevent relapse in all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.